These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6635445)

  • 1. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis.
    Jones RB; Ridgway GL; Boulding S; Hunley KL
    Rev Infect Dis; 1983; 5 Suppl 3():S556-61. PubMed ID: 6635445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.
    Kutlin A; Kohlhoff S; Roblin P; Hammerschlag MR; Riska P
    Antimicrob Agents Chemother; 2005 Mar; 49(3):903-7. PubMed ID: 15728882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis.
    Zanetti S; Usai D; Nonis A; Fadda G
    J Antimicrob Chemother; 1996 Feb; 37(2):357-9. PubMed ID: 8707747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro studies of Chlamydia trachomatis susceptibility and resistance to rifampin and rifabutin.
    Treharne JD; Yearsley PJ; Ballard RC
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1393-4. PubMed ID: 2552911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro susceptibility studies of FCE 22250 and rifampicin on Legionella and Chlamydia trachomatis strains.
    Zanetti S; Ungheri D; Castellani Pastoris M; Fadda G
    Drugs Exp Clin Res; 1987; 13(10):631-4. PubMed ID: 3428127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative resistance to erythromycin in Chlamydia trachomatis.
    Mourad A; Sweet RL; Sugg N; Schachter J
    Antimicrob Agents Chemother; 1980 Nov; 18(5):696-8. PubMed ID: 7447426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil.
    Suchland RJ; Bourillon A; Denamur E; Stamm WE; Rothstein DM
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1120-6. PubMed ID: 15728912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic susceptibility of Chlamydia trachomatis.
    Blackman HJ; Yoneda C; Dawson CR; Schachter J
    Antimicrob Agents Chemother; 1977 Dec; 12(6):673-7. PubMed ID: 931365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis.
    Xia M; Suchland RJ; Carswell JA; Van Duzer J; Buxton DK; Brown K; Rothstein DM; Stamm WE
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3974-6. PubMed ID: 16127086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.
    Dreses-Werringloer U; Padubrin I; Zeidler H; Köhler L
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3001-8. PubMed ID: 11600348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth cycle-dependent pharmacodynamics of antichlamydial drugs.
    Siewert K; Rupp J; Klinger M; Solbach W; Gieffers J
    Antimicrob Agents Chemother; 2005 May; 49(5):1852-6. PubMed ID: 15855506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of fleroxacin against Chlamydia trachomatis.
    Steele-Mortimer O; Meier-Ewert H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():65-70. PubMed ID: 3144551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of rifaximin, a topical rifamycin derivative, against Chlamydia trachomatis.
    Prasad ES; Wenman WM
    Diagn Microbiol Infect Dis; 1993 Feb; 16(2):135-6. PubMed ID: 8467625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chlamydia trachomatis: in vitro susceptibility to antibiotics singly and in combination.
    Christensen JJ; Holten-Andersen W; Nielsen PB
    Acta Pathol Microbiol Immunol Scand B; 1986 Oct; 94(5):329-32. PubMed ID: 3788573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.
    Murphy CK; Mullin S; Osburne MS; van Duzer J; Siedlecki J; Yu X; Kerstein K; Cynamon M; Rothstein DM
    Antimicrob Agents Chemother; 2006 Mar; 50(3):827-34. PubMed ID: 16495239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Minimum inhibitory concentration and minimum bactericidal concentration of tetracycline and erythromycin in 35 recent Munich isolates of Chlamydia trachomatis].
    Korting HC; Hartinger A
    Hautarzt; 1988 Mar; 39(3):161-5. PubMed ID: 3378887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The activity of rifampin and analogs against Staphylococcus epidermidis biofilms in a CAPD environment model.
    Obst G; Gagnon RF; Harris A; Prentis J; Richards GK
    Am J Nephrol; 1989; 9(5):414-20. PubMed ID: 2801789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activity of RU 28965 against Chlamydia trachomatis.
    Cevenini R; Sambri V; La Placa M
    Eur J Clin Microbiol; 1986 Oct; 5(5):598-600. PubMed ID: 3536506
    [No Abstract]   [Full Text] [Related]  

  • 19. An in-vitro investigation of synergy and antagonism between antimicrobials against Chlamydia trachomatis.
    How SJ; Hobson D; Hart CA; Webster RE
    J Antimicrob Chemother; 1985 May; 15(5):533-8. PubMed ID: 4008386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of genes and mutations associated with Chlamydiae species' resistance to antibiotics.
    Benamri I; Azzouzi M; Sanak K; Moussa A; Radouani F
    Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):59. PubMed ID: 34479551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.